236 related articles for article (PubMed ID: 18702871)
1. Predictive factors of all-trans-retinoic acid related complications during induction therapy for acute promyelocytic leukemia.
Jeddi R; Kacem K; Ben Neji H; Mnif S; Gouider E; Aissaoui L; Ben Amor R; Ben Lakhal R; Ben Abid H; Belhadjali Z; Meddeb B
Hematology; 2008 Jun; 13(3):142-6. PubMed ID: 18702871
[TBL] [Abstract][Full Text] [Related]
2. Treatment of acute promyelocytic leukemia with PETHEMA LPA 99 protocol: a Tunisian single center experience.
Jeddi R; Ghédira H; Menif S; Ben Neji H; Ben Amor R; Kacem K; Aissaoui L; Bouteraâ W; Abdennebi Y; Raihane BL; Gouider E; Raouf H; Hèla BA; Saad A; Zaher B; Meddeb B
Hematology; 2010 Aug; 15(4):204-9. PubMed ID: 20670478
[TBL] [Abstract][Full Text] [Related]
3. Outcome of childhood acute promyelocytic leukemia with all-trans-retinoic acid and chemotherapy.
de Botton S; Coiteux V; Chevret S; Rayon C; Vilmer E; Sanz M; de La Serna J; Philippe N; Baruchel A; Leverger G; Robert A; San Miguel J; Conde E; Sotto JJ; Bordessoule D; Fegueux N; Fey M; Parry A; Chomienne C; Degos L; Fenaux P
J Clin Oncol; 2004 Apr; 22(8):1404-12. PubMed ID: 15084614
[TBL] [Abstract][Full Text] [Related]
4. Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): benefit of an early intervention.
Esteve J; Escoda L; Martín G; Rubio V; Díaz-Mediavilla J; González M; Rivas C; Alvarez C; González San Miguel JD; Brunet S; Tomás JF; Tormo M; Sayas MJ; Sánchez Godoy P; Colomer D; Bolufer P; Sanz MA;
Leukemia; 2007 Mar; 21(3):446-52. PubMed ID: 17205057
[TBL] [Abstract][Full Text] [Related]
5. Effect of all-trans-retinoic acid alone or in combination with chemotherapy in newly diagnosed acute promyelocytic leukaemia.
Colović MD; Janković GM; Elezović I; Vidović A; Bila JS; Novak A; Babić D
Med Oncol; 1997 Jun; 14(2):65-72. PubMed ID: 9330265
[TBL] [Abstract][Full Text] [Related]
6. Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. The European APL Group.
De Botton S; Dombret H; Sanz M; Miguel JS; Caillot D; Zittoun R; Gardembas M; Stamatoulas A; Condé E; Guerci A; Gardin C; Geiser K; Makhoul DC; Reman O; de la Serna J; Lefrere F; Chomienne C; Chastang C; Degos L; Fenaux P
Blood; 1998 Oct; 92(8):2712-8. PubMed ID: 9763554
[TBL] [Abstract][Full Text] [Related]
7. Childhood acute promyelocytic leukemia: no benefit of all-trans-retinoic acid administered in a short-course schedule.
Zubizarreta PA; Rose AB; Felice MS; Alfaro E; Delfino S; Cygler AM; Sackmann-Muriel F
Pediatr Hematol Oncol; 2000 Mar; 17(2):155-62. PubMed ID: 10734658
[TBL] [Abstract][Full Text] [Related]
8. Single-agent liposomal all-trans retinoic acid can cure some patients with untreated acute promyelocytic leukemia: an update of The University of Texas M. D. Anderson Cancer Center Series.
Tsimberidou AM; Tirado-Gomez M; Andreeff M; O'Brien S; Kantarjian H; Keating M; Lopez-Berestein G; Estey E
Leuk Lymphoma; 2006 Jun; 47(6):1062-8. PubMed ID: 16840198
[TBL] [Abstract][Full Text] [Related]
9. All-trans retinoic acid (ATRA) in the treatment of acute promyelocytic leukemia (APL).
Chim CS; Kwong YL; Liang R; Chu YC; Chan CH; Chan LC; Wong KF; Chan TK
Hematol Oncol; 1996 Sep; 14(3):147-54. PubMed ID: 9119359
[TBL] [Abstract][Full Text] [Related]
10. All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol.
Tallman MS; Andersen JW; Schiffer CA; Appelbaum FR; Feusner JH; Woods WG; Ogden A; Weinstein H; Shepherd L; Willman C; Bloomfield CD; Rowe JM; Wiernik PH
Blood; 2002 Dec; 100(13):4298-302. PubMed ID: 12393590
[TBL] [Abstract][Full Text] [Related]
11. [Acute promyelocytic leukemia: results of the Chilean protocol LPA2000].
Undurraga MS; Puga B; Cabrera ME; Palma T; Rossle A; Vergara CG; Rojas B; Aspillaga A
Rev Med Chil; 2013 Oct; 141(10):1231-9. PubMed ID: 24522350
[TBL] [Abstract][Full Text] [Related]
12. All-trans retinoic acid therapy in relapsed/refractory or newly diagnosed acute promyelocytic leukemia (APL) in Japan.
Ohno R; Ohnishi K; Takeshita A; Tanimoto M; Murakami H; Kanamaru A; Asou N; Kobayashi T; Kuriyama K; Ohmoto E
Leukemia; 1994; 8 Suppl 3():S64-9. PubMed ID: 7808028
[TBL] [Abstract][Full Text] [Related]
13. [Effect of all-trans retinoic acid on the newly diagnosed acute promyelocytic leukaemia: our experience].
Rolovitsh Z; Cholovitsh M; Elezovitsh I; Vidovitsh A; Radoshevitsh-Radojkovitsh N; Boshkovitsh D; Novak A; Basara N
Srp Arh Celok Lek; 1995; 123(11-12):279-85. PubMed ID: 16296239
[TBL] [Abstract][Full Text] [Related]
14. Long-term survival and prognostic study in acute promyelocytic leukemia treated with all-trans-retinoic acid, chemotherapy, and As2O3: an experience of 120 patients at a single institution.
Hu J; Shen ZX; Sun GL; Chen SJ; Wang ZY; Chen Z
Int J Hematol; 1999 Dec; 70(4):248-60. PubMed ID: 10643151
[TBL] [Abstract][Full Text] [Related]
15. Acute promyelocytic leukemia: all-trans retinoic acid (ATRA) along with chemotherapy is superior to ATRA alone.
Advani SH; Nair R; Bapna A; Gladstone B; Kadam P; Saikia TK; Parekh PM; Gopal R; Nair CN
Am J Hematol; 1999 Feb; 60(2):87-93. PubMed ID: 9929098
[TBL] [Abstract][Full Text] [Related]
16. Thrombosis in patients with acute promyelocytic leukemia treated with and without all-trans retinoic acid.
Escudier SM; Kantarjian HM; Estey EH
Leuk Lymphoma; 1996 Feb; 20(5-6):435-9. PubMed ID: 8833399
[TBL] [Abstract][Full Text] [Related]
17. Treatment with all-trans retinoic acid and anthracycline monochemotherapy for children with acute promyelocytic leukemia: a multicenter study by the PETHEMA Group.
Ortega JJ; Madero L; Martín G; Verdeguer A; García P; Parody R; Fuster J; Molines A; Novo A; Debén G; Rodríguez A; Conde E; de la Serna J; Allegue MJ; Capote FJ; González JD; Bolufer P; González M; Sanz MA;
J Clin Oncol; 2005 Oct; 23(30):7632-40. PubMed ID: 16234524
[TBL] [Abstract][Full Text] [Related]
18. CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous all-trans-retinoic acid and chemotherapy.
Ferrara F; Morabito F; Martino B; Specchia G; Liso V; Nobile F; Boccuni P; Di Noto R; Pane F; Annunziata M; Schiavone EM; De Simone M; Guglielmi C; Del Vecchio L; Lo Coco F
J Clin Oncol; 2000 Mar; 18(6):1295-300. PubMed ID: 10715300
[TBL] [Abstract][Full Text] [Related]
19. All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia. Japan Adult Leukemia Study Group.
Kanamaru A; Takemoto Y; Tanimoto M; Murakami H; Asou N; Kobayashi T; Kuriyama K; Ohmoto E; Sakamaki H; Tsubaki K
Blood; 1995 Mar; 85(5):1202-6. PubMed ID: 7858250
[TBL] [Abstract][Full Text] [Related]
20. Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Japan Adult Leukemia Study Group.
Asou N; Adachi K; Tamura J; Kanamaru A; Kageyama S; Hiraoka A; Omoto E; Akiyama H; Tsubaki K; Saito K; Kuriyama K; Oh H; Kitano K; Miyawaki S; Takeyama K; Yamada O; Nishikawa K; Takahashi M; Matsuda S; Ohtake S; Suzushima H; Emi N; Ohno R
J Clin Oncol; 1998 Jan; 16(1):78-85. PubMed ID: 9440726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
